Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN54gp140 + GLA-AF (Imperial College London)
- Development stage
- Phase 1
- Lead developer
- Imperial College London
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CN54gp140 + GLA-AF is a recombinant protein-based HIV-1 vaccine candidate developed by Imperial College London. It consists of a trimeric envelope glycoprotein derived from a clade C HIV-1 strain (CN54), which is the most prevalent subtype in the global epidemic. The vaccine is formulated with GLA-AF (glucopyranosyl lipid A-aqueous formulation), a synthetic Toll-like receptor 4 (TLR4) agonist adjuvant designed to enhance the magnitude and breadth of the immune response. The vaccine aims to elicit both systemic and mucosal antibodies to prevent HIV-1 infection. Clinical evaluation has focused on Phase 1 trials assessing safety, tolerability, and immunogenicity in healthy, HIV-uninfected adults.
- Other names
- CN54gp140 HIV vaccineCN-54gp140 HIV vaccineCN 54gp140 HIV vaccineCN54gp140/GLA-AF
02
Targets
CD14 (Monocyte differentiation antigen CD14)Human immunodeficiency virus 1 envelope glycoprotein epitopesMHC II (Major histocompatibility complex class II receptor)MYD88 (Myeloid differentiation primary response protein MyD88)TRIF (TIR-domain-containing adapter-inducing interferon-beta)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on CN54gp140 + GLA-AF (Imperial College London).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN54gp140 + GLA-AF (Imperial College London).